Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050463 · ClinicalTrials.gov registry record
Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer
A clinical trial of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, sponsored by Stanford University.
- Completed
- Registry status
- 178
- Enrollment target
- 1
- Study location
NCT03050463: Completed study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, sponsored by Stanford University.
NCT03050463 is a study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer that has completed, run by Stanford University. The registered enrollment target is 178 participants, below the 275-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03050463, a study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 178 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety by non-surgical means.
Primary Outcome
Multivariate regression analysis will be used to examine affect reactivity among women with a recent diagnosis of breast cancer in comparison to healthy controls at baseline. Functional data will be collected on the explicit affect regulation task (20 minutes) and explicit cancer related affect regulation task (8 minutes). Affect reactivity and cancer-related affect reactivity will be defined by WATCH negative minus WATCH neutral and by WATCH cancer-related negative and WATCH neutral contrast. T
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
- PROCEDURE Functional Magnetic Resonance Imaging
Study Locations (1)
California
- Stanford University, School of Medicine - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-07-08 |
What the finished NCT03050463 record still lists
NCT03050463 is an observational study that tracks outcomes without assigning an intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, below the 275-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (35% lower).
The record links to 9 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT03050463 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03050463 about?
NCT03050463 is a clinical study titled "Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer". The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety ...
What is the current status of trial NCT03050463?
This trial is currently completed. The enrollment target is 178 participants. The study started on 2016-08. Estimated completion is 2021-07-08.
What conditions does trial NCT03050463 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Healthy Subject.
What interventions are being tested in trial NCT03050463?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Functional Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03050463?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03050463 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03050463's enrollment target sits among peer trials
178 8th of 29 higher than 22 of 29 other Stage IIIA Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IIIA Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642002 · 178 participants · NA
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
- NCT04227847 · 178 participants · Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- NCT04855214 · 178 participants
Evaluating the Experience of Upper Limb Prosthesis Use
- NCT05391126 · 178 participants · NA
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia